223 related articles for article (PubMed ID: 33061853)
1. Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer.
Huang Y; Wu H; Li X
Cancer Cell Int; 2020; 20():501. PubMed ID: 33061853
[TBL] [Abstract][Full Text] [Related]
2. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
4. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
5. Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro.
Sai S; Vares G; Kim EH; Karasawa K; Wang B; Nenoi M; Horimoto Y; Hayashi M
Mol Cancer; 2015 Sep; 14():166. PubMed ID: 26338199
[TBL] [Abstract][Full Text] [Related]
6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
7.
Ma G; Liu C; Lian W; Zhang Y; Yuan H; Zhang Y; Song S; Yang Z
Ann Nucl Med; 2021 May; 35(5):600-607. PubMed ID: 33689138
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
[TBL] [Abstract][Full Text] [Related]
9. TROP2 regulates cisplatin sensitivity of triple-negative breast cancer cells by regulating endoplasmic reticulum stress.
Zhang M; Xu J; Liu Q; Yan X; Li N
Histol Histopathol; 2024 May; ():18771. PubMed ID: 38884164
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib.
Yu Y; Liao H; Xie R; Zhang Y; Zheng R; Chen J; Zhang B
Front Oncol; 2020; 10():590813. PubMed ID: 33330073
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product.
Elangovan S; Hsieh TC; Wu JM
Anticancer Res; 2008; 28(5A):2641-7. PubMed ID: 19035289
[TBL] [Abstract][Full Text] [Related]
13. KIFC1: A Reliable Prognostic Biomarker in Rb-positive Triple-negative Breast Cancer Patients Treated With Doxorubicin in Combination With Abemaciclib.
Fleisher B; Werkman C; Jacobs B; Varkey J; Taha K; Ait-Oudhia S
Cancer Diagn Progn; 2022; 2(5):525-532. PubMed ID: 36060015
[TBL] [Abstract][Full Text] [Related]
14. Progress with palbociclib in breast cancer: latest evidence and clinical considerations.
Rocca A; Schirone A; Maltoni R; Bravaccini S; Cecconetto L; Farolfi A; Bronte G; Andreis D
Ther Adv Med Oncol; 2017 Feb; 9(2):83-105. PubMed ID: 28203301
[TBL] [Abstract][Full Text] [Related]
15. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
Ji J; Zhang Z; He X; Pan G; Li G; Lv J; Xu Y; Xie M; Feng J; Wang W; Liu B; Ma J; Wang X
Anticancer Drugs; 2023 Aug; 34(7):803-815. PubMed ID: 36729405
[TBL] [Abstract][Full Text] [Related]
16. In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Fleisher B; Lezeau J; Werkman C; Jacobs B; Ait-Oudhia S
Breast Cancer (Dove Med Press); 2021; 13():87-105. PubMed ID: 33628047
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.
Cretella D; Fumarola C; Bonelli M; Alfieri R; La Monica S; Digiacomo G; Cavazzoni A; Galetti M; Generali D; Petronini PG
Sci Rep; 2019 Sep; 9(1):13014. PubMed ID: 31506466
[TBL] [Abstract][Full Text] [Related]
18. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
19. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
[TBL] [Abstract][Full Text] [Related]
20. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]